Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma.

Onco Targets Ther · 2009 · PMC2886339 · PMID 20616907

Europe PMC DOI

hedged sentences

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

showed a trendP = 0.062so close (0.05 < p ≤ 0.1)

13 The time to progression (TTP) and the duration of response were not significantly different, although patients with FL treated with 90 Y-IT showed a trend towards longer TTP (12.6 months vs 10.2 months, P = 0.062) and achieved more often responses lasting longer than 6 months (74% vs 52%, P = 0.019) compared to patients in the rituximab control group.

also in 53,322 other papers

highly significantno p-value reported

2 Large randomized clinical studies confirmed the benefit of adding the anti-CD20 monoclonal antibody rituximab to combination chemotherapy regimes with highly significant improvement in progression-free (PFS) and even overall survival (OS). 3 – 6 A helpful clinical advance has been the development of the FL international prognostic index (FLIPI). 7 The FLIPI stratifies patients into risk groups.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.